Bio-Rad Laboratories, Inc.

Equities

BIO

US0905722072

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 13:41:37 2024-05-09 EDT 5-day change 1st Jan Change
272.8 USD +1.71% Intraday chart for Bio-Rad Laboratories, Inc. -1.86% -15.11%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
UBS Adjusts Price Target on Bio-Rad Laboratories to $385 From $420, Maintains Buy Rating MT
RBC Adjusts Price Target on Bio-Rad Laboratories to $414 From $420 MT
Citigroup Adjusts Price Target on Bio-Rad Laboratories to $300 From $365 MT
Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip RE
Bio-Rad Laboratories Q1 Non-GAAP Earnings, Revenue Decline MT
Transcript : Bio-Rad Laboratories, Inc., Q1 2024 Earnings Call, May 07, 2024
Earnings Flash (BIO) BIO-RAD LABORATORIES Reports Q1 Revenue $610.8M, vs. Street Est of $620.1M MT
Earnings Flash (BIO) BIO-RAD LABORATORIES Reports Q1 EPS $2.29, vs. Street Est of $2.14 MT
Bio-Rad Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
RBC Capital Adjusts Price Target on Bio-Rad Laboratories to $420 From $474 MT
Bio-Rad Laboratories, Inc. Announces Executive Vice President and President Changes, Life Science Group CI
Zacks Investment Research Lowers Price Target on Bio-Rad Laboratories to $285 From $322 MT
Oncocyte Corporation and Bio-Rad Laboratories, Inc. Partner on Global Launch of Transplant Assay CI
Bio-Rad Laboratories COO Andrew Last to Retire in September MT
Bio-Rad Laboratories, Inc. Announces Chief Operating Officer Andrew Last to Retire CI
RBC Trims Price Target on Bio-Rad Laboratories to $474 From $480, Keeps Outperform Rating MT
North American Morning Briefing : Focus Turns to -2- DJ
Citigroup Downgrades Bio-Rad Laboratories to Neutral From Buy, Adjusts Price Target to $365 From $400 MT
Biodesix Strikes New Research Deal With Memorial Sloan Kettering Cancer Center MT
Bio-Rad Laboratories Appoints Roop Lakkaraju as CFO MT
Bio-Rad Laboratories, Inc. Appoints Roop K. Lakkaraju as Chief Financial Officer, Effective April 15, 2024 CI
Bio-Rad Laboratories, Inc. Appoints Roop K. Lakkaraju as New Executive Vice President Effective April 15, 2024 CI
Transcript : Bio-Rad Laboratories, Inc. Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 02:30 PM
Bio-rad Laboratories Insider Sold Shares Worth $1,008,000, According to a Recent SEC Filing MT
UBS Adjusts Bio-Rad Laboratories Price Target to $420 From $395, Maintains Buy Rating MT
Chart Bio-Rad Laboratories, Inc.
More charts
Bio-Rad Laboratories, Inc. is specialized in the development, manufacturing and marketing of products used in life sciences research, clinical diagnostics and analytical chemistry. Net sales break down by activity as follows: - manufacture of clinical diagnostic tests and automated test systems (51.8%). The group also offers test kits, quality control systems and related IT systems; - manufacture of reagents, equipment and instruments for biological research (48.1%): for the separation, identification and purification of chemical and biological substances (proteins, nucleic acids, bacteria, etc.) for the proteomics, genomics research, biopharmaceuticals, cell biology and food safety markets; - other (0.1%): in particular, manufacturing of analytical instruments. At the end of 2022, the Group has 16 production sites in the United States (5), Germany (3), France (2), China (2), Poland, the United Kingdom, Switzerland and Singapore. Net sales are distributed geographically as follows: the United States (41.2%), Europe (30.4%), Asia (22.8%) and other (5.6%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
268.3 USD
Average target price
401.7 USD
Spread / Average Target
+49.73%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. BIO Stock
  4. News Bio-Rad Laboratories, Inc.
  5. RBC Trims Price Target on Bio-Rad Laboratories to $480 From $484, Keeps Outperform Rating
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW